Shopping Cart
- Remove All
- Your shopping cart is currently empty
DNJ-20 is an α-glucosidase inhibitor with an IC50 of 55.3 μg/mL. It exhibits broad-spectrum activity against SARS-CoV-2. By interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), DNJ-20 hinders the proper processing of viral glycoproteins, thus blocking the formation and infection of viral particles. It is effective against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43, with IC50 values reaching up to 1.49 μM. DNJ-20 can be utilized for pan-coronavirus research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | DNJ-20 is an α-glucosidase inhibitor with an IC50 of 55.3 μg/mL. It exhibits broad-spectrum activity against SARS-CoV-2. By interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), DNJ-20 hinders the proper processing of viral glycoproteins, thus blocking the formation and infection of viral particles. It is effective against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43, with IC50 values reaching up to 1.49 μM. DNJ-20 can be utilized for pan-coronavirus research. |
Molecular Weight | 587.658 |
Formula | C31H41NO10 |
Cas No. | 3081926-49-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.